Overview

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Status:
Completed

Trial end date:
2011-02-03

Target enrollment:

Participant gender:

Summary

This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.

Phase:

Phase 2

Details

Lead Sponsor:

Nabriva Therapeutics AG

Treatments:

Lefamulin
Vancomycin